Page last updated: 2024-11-10

sk&f-96356

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo(3,2-c)quinoline: a K+-competitive fluorescent inhibitor of the H,K-ATPase; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3081211
CHEMBL ID54511
SCHEMBL ID9685793
MeSH IDM0190027

Synonyms (16)

Synonym
1-mdpq
sk&f 96356
sk&f-96356
1h-pyrrolo(3,2-c)quinolin-4-amine, 2,3-dihydro-n,6-dimethyl-1-(2-methylphenyl)-
122456-37-5
1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo(3,2-c)quinoline
skf 96356
CHEMBL54511 ,
n,6-dimethyl-1-(2-methylphenyl)-2,3-dihydropyrrolo[3,2-c]quinolin-4-amine
bdbm50000675
methyl-(6-methyl-1-o-tolyl-2,3-dihydro-1h-pyrrolo[3,2-c]quinolin-4-yl)-amine
SCHEMBL9685793
1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo[3,2-c]quinoline
XZENCZPCSRXPSL-UHFFFAOYSA-N ,
DTXSID20153623
1-(2-methylphenyl)-4-methylamino-6-methyl-2,3-dihydropyrrolo(3,2-c) quinoline

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Some compounds also proved to be effective inhibitors of stimulated acid secretion in both the rat and dog when dosed intravenously."( Reversible inhibitors of the gastric (H+/K+)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines.
Blurton, P; Brown, TH; Ife, RJ; Keeling, DJ; Leach, CA; Meeson, ML; Parsons, ME; Theobald, CJ, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID78894Inhibition of K+ stimulated gastric ATPase activity1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Reversible inhibitors of the gastric (H+/K+)-ATPase. 5. Substituted 2,4-diaminoquinazolines and thienopyrimidines.
AID180189The compound was evaluated for the gastric antisecretory activity in the lumen-perfused rat on intravenous administration1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Reversible inhibitors of the gastric (H+/K+)-ATPase. 2. 1-Arylpyrrolo[3,2-c]quinolines: effect of the 4-substituent.
AID185134Percentage inhibition of rat gastric secretion following 10 uM/Kg i.p.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Reversible inhibitors of the gastric (H+/K+)-ATPase. 2. 1-Arylpyrrolo[3,2-c]quinolines: effect of the 4-substituent.
AID87766The compound was evaluated for the gastric antisecretory activity in the Heidenhain pouch dog for a dose of 4 umol/kg on intravenous administration1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Reversible inhibitors of the gastric (H+/K+)-ATPase. 2. 1-Arylpyrrolo[3,2-c]quinolines: effect of the 4-substituent.
AID87764The compound was evaluated for the gastric antisecretory activity in the Heidenhain pouch dog for a dose of 1 umol/kg on intravenous administration1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Reversible inhibitors of the gastric (H+/K+)-ATPase. 2. 1-Arylpyrrolo[3,2-c]quinolines: effect of the 4-substituent.
AID79078Inhibition of rat isolated gastric (H(+)/K(+))-ATPase.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
Reversible inhibitors of the gastric (H+/K+)-ATPase. 2. 1-Arylpyrrolo[3,2-c]quinolines: effect of the 4-substituent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (42.86)18.2507
2000's6 (42.86)29.6817
2010's2 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.61 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]